宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

交易中 11-10 14:29:53

2.740

-0.030

-1.08%

最高2.810	最低2.730	成交量20.68万
今开2.770	昨收2.770	日振幅2.89%
总市值11.75亿	流通市值11.45亿	总股本4.29亿
成交额57.46万	换手率0.05%	流通股本4.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":2.74,"timestamp":1794292089779,"preClose":2.77,"halted":0,"volume":206800,"delay":0,"changeRate":-0.010830324909747223,"floatShares":418000000,"shares":429000000,"eps":-0.53,"marketStatus":"交易中","change":-0.03,"latestTime":"11-10 14:29:53","open":2.77,"high":2.81,"low":2.73,"amount":574557,"amplitude":0.028881,"askPrice":2.765,"askSize":3000,"bidPrice":2.74,"bidSize":5400,"shortable":0,"etf":0,"ttmEps":-0.626036,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1794298200000},"marketStatusCode":2,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":2.77,"openAndCloseTimeList":[[1794274200000,1794283200000],[1794286800000,1794297600000]],"volumeRatio":0.978897,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"1131063067","title":"宜明昂科-B2026年10月股份变动月报：总股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1131063067","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131063067?lang=zh_cn&edition=full","pubTime":"2026-11-05 14:21","pubTimestamp":1793859675,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术(上海)股份有限公司于2026年11月5日发布2026年10月股份变动月报表。报告期内，公司注册股本维持在人民币431,507,695元，未发生变动。截至10月底，库存股份合计2,571,400股，较上月增加228,600股。非上市股份数量11,030,390股保持不变。公司于报告期内无其他新增发行、期权、可换股债券或其他股份权益的变动事项。截至2026年10月底，公司总股本仍维持420,477,305股，确认符合香港联交所《上市规则》有关公众持股量的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186379617","title":"宜明昂科-B（01541）拟更换核数师　德勤辞任　中汇安达获提名接棒","url":"https://stock-news.laohu8.com/highlight/detail?id=1186379617","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186379617?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:45","pubTimestamp":1793198743,"startTime":"0","endTime":"0","summary":"10月28日，宜明昂科生物医药技术（上海）股份有限公司公告称，原核数师德勤·关黄陈方会计师行已向公司辞任，原因系附属公司增资及相关交易导致审计工作量增加，双方未能就截至2026年12月31日止年度综合财务报表的新增审计费用达成一致。德勤确认无其他事项需提请股东及债权人注意，董事会及审计委员会亦确认双方不存在未解决分歧。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678491987","title":"宜明昂科-B(01541.HK)建议委任中汇为核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2678491987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678491987?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:42","pubTimestamp":1793198526,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145947816","title":"宜明昂科-B(01541)10月22日回购3.82万股股份，耗资约11.44万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145947816","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145947816?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:06","pubTimestamp":1792663579,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年10月22日公告，其在香港联交所场内回购股份，数量为38,200股，占2026年10月14日公司已发行股份总数的约0.0091%。回购价区间介于每股2.945港元至3港元，总耗资约11.44万港元。回购完成后，公司已发行股本由417,944,105股减少至417,905,905股，库藏股数量由2,533,200股增至2,571,400股，总股本维持在420,477,305股。根据此前于2026年5月28日通过的回购授权，宜明昂科-B可回购的股份总数为43,150,769股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B(01541)10月22日回购3.82万股股份，耗资约11.44万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677959678","title":"宜明昂科-B(01541.HK)10月22日斥资11.44万港元回购3.82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677959678","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677959678?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:04","pubTimestamp":1792663475,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121420382","title":"宜明昂科-B回购5.6万股股份，耗资约16.97万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121420382","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121420382?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:37","pubTimestamp":1791977838,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年10月14日发布翌日披露报表，公告于香港联交所场内回购公司H股普通股。根据公告，宜明昂科-B在2026年10月14日回购56,000股H股股份，占当日前已发行股本的约0.0134%。本次回购价格区间为每股港币2.985港元至3.06港元，总代价约为16.97万港元。本次回购完成后，公司已发行股份总数由418,000,105股减少至417,944,105股；公司库存股份数量由2,477,200股增加至2,533,200股，合计股本为420,477,305股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B回购5.6万股股份，耗资约16.97万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675411663","title":"宜明昂科10月14日回购56000股H股 耗资约16.97万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675411663","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675411663?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:37","pubTimestamp":1791977820,"startTime":"0","endTime":"0","summary":"10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与项飙现场对话！\n名额有限，手慢无。让我们共赴可持续之约！【点击报名】10月14日，宜明昂科-B(01541.HK)于2026年10月14日在香港联交所回购56000股H股，每股回购价最高HKD3.06、最低HKD2.985，付出的价格总额为HKD16.97万。回购股份拟持作库存股份，拟注销数目为0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-10-14/doc-inivezmf8384606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675349300","title":"宜明昂科-B(01541)10月14日斥资16.97万港元回购5.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675349300","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675349300?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:35","pubTimestamp":1791977755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年10月14日斥资16.97万港元回购5.6万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122316410","title":"宜明昂科-B 10月13日回购13.44万股股份，涉资约40.43万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122316410","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122316410?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:52","pubTimestamp":1791888720,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年10月13日发布翌日披露报表，公告显示，公司于当日通过香港联交所场内回购13.44万股H股，占本次事件前已发行股份约0.0321%。回购价格区间介乎每股2.92港元至3.10港元，合计耗资约40.43万港元。回购完成后，公司已发行股份数量变更为418,000,105股，库藏股数量增至2,477,200股，已发行股份总数维持在420,477,305股。公司确认，前述回购已经获得其董事会正式授权，相关程序均符合香港联交所证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B 10月13日回购13.44万股股份，涉资约40.43万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675355505","title":"宜明昂科-B(01541)10月13日斥资40.43万港元回购13.44万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675355505","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675355505?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:47","pubTimestamp":1791888455,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年10月13日斥资40.43万港元回购13.44万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111208751","title":"宜明昂科-B发布9月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1111208751","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111208751?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:47","pubTimestamp":1791276460,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年10月6日发布2026年9月股份变动月报显示，截至2026年9月30日，公司注册股本合计为人民币431,507,695元，较上月无新增或减少。报告期内，宜明昂科-B的H股注册数量为420,477,305股，与上月持平；非上市股份注册数量为11,030,390股，同样较上月无变动。公司通过在港交所回购321,000股H股并持作库存股份完成了上述变动，共涉及9月4日至9月29日期间的多次操作，回购价格区间约为每股3.2176至3.4693港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106554614","title":"宜明昂科-B回购70,600股股份，涉资约23.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106554614","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106554614?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:46","pubTimestamp":1790682376,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年9月29日公告称，公司于香港联合交易所回购70,600股H股，占该公司回购前已发行股份总数约0.0169%。本次回购价格区间介乎每股3.265港元至3.415港元，总耗资约23.69万港元。根据此前获得的回购授权，宜明昂科生物医药技术（上海）股份有限公司可回购最多43,150,769股。公司确认是次回购已获董事会正式批准，并已遵守香港联合交易所上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购70,600股股份，涉资约23.69万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671287219","title":"宜明昂科-B(01541)9月29日斥资23.69万港元回购7.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671287219","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671287219?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:44","pubTimestamp":1790682292,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年9月29日斥资23.69万港元回购7.06万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671473291","title":"港股异动 | 宜明昂科-B(01541.HK)涨超6% IMM0306重磅Ib/IIa期临床数据披露 有望成为增厚利润关键一环","url":"https://stock-news.laohu8.com/highlight/detail?id=2671473291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671473291?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:43","pubTimestamp":1790667788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157035185","title":"宜明昂科-B完成50百万元子公司增资 继续持股68.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157035185","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157035185?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:45","pubTimestamp":1790606742,"startTime":"0","endTime":"0","summary":"2026年9月28日，宜明昂科生物医药技术（上海）股份有限公司发布自愿公告称，其对子公司宜明凯尔生物医药技术（上海）有限公司的增资及相关工商登记手续已全部完成。根据公告，投资者已按照增资协议向目标公司注入对价人民币50百万元。目标公司仍为宜明昂科-B的非全资附属公司，其财务业绩将继续并入集团财务报表。本次增资事项最初于2026年8月7日公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670255434","title":"宜明昂科-B(01541)附属宜明凯尔生物医药技术(上海)完成增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2670255434","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670255434?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:40","pubTimestamp":1790606412,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，内容有关附属宜明凯尔生物医药技术(上海)获增资5000万元。于本公告日期，增资及有关增资的相关工商登记程序已完成。投资者已根据增资协议完成支付人民币5000万元的对价。增资完成后，目标公司宜明凯尔生物医药技术(上海)有限公司分别由公司、嘉兴昶新、生科起航、新界创元及王先生持有约68.34%、15.83%、6.33%、6.33%及3.17%股权。因此，目标公司仍为公司非全资附属公司，且其财务业绩继续并入集团财务报表。目标公司主要从事开发代谢性疾病及罕见病创新药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","BK4588","01541","BK4581","161726","BK1161","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177951173","title":"宜明昂科-B 2026年中期营收2,542.40万元，经调整净亏损1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177951173","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177951173?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:33","pubTimestamp":1790606029,"startTime":"0","endTime":"0","summary":"2026年上半年，宜明昂科-B实现营收2,542.40万元，同比下降33.20%。公司同期实现经调整净亏损1.62亿元，同比扩大12.50%。\n从成本端看，报告期内，研发费用为1.55亿元，同比下降7.90%，主要由于部分临床前与生产开支减少所致；管理开支为2,319.10万元，同比下降14.90%。经营活动所用现金净额为1.60亿元，同比上升22.20%。\n在分业务方面，合作开发收入2,525.20万元，同比下降33.50%；测试服务收入15.80万元，与去年同期持平；细胞株及其他产品收入1.40万元，同比下降56.30%。公司将继续推进核心在研项目的临床与商业化进程，进一步夯实研发管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 2026年中期营收2,542.40万元，经调整净亏损1.62亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669458554","title":"宜明昂科-B(01541)：新一代MCE分子，重磅Ib/IIa期临床数据披露，再次确认IMM0306差异化创新优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2669458554","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669458554?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:31","pubTimestamp":1790213485,"startTime":"0","endTime":"0","summary":"在今年8月21日系统性红斑狼疮适应症获得美国FDA的IND许可后，宜明昂科-B自主研发的靶向CD47和CD20的双特异性分子阿沐瑞芙普α再次迎来一个里程碑利好。相较于已上市BTK抑制剂的ORR 57.8%和CRR 12%，IMM0306联合来那度胺方案有望为MZL患者提供更加高效的治疗选择。结语随着此次IMM0306在两项适应症上的重磅数据披露，让宜明昂科在差异化原研创新方面的确定性得到进一步确认。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187681225","title":"宜明昂科-B9月16日回购9.24万股股份，耗资约29.76万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187681225","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187681225?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:52","pubTimestamp":1789555968,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年9月16日公布翌日披露报表，披露最新回购交易信息。公司于当日于香港联合交易所场内回购合计92,400股H股，占公司现有已发行股份总数的约0.0221%。回购价范围介乎每股3.155港元至3.27港元，回购数量对应的成交量加权平均价为每股3.2205港元，合计支付金额约29.76万港元。回购完成后，宜明昂科-B已发行股份为418,205,105股，库藏股数增至2,272,200股，公司整体已发行股份总数维持于420,477,305股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B9月16日回购9.24万股股份，耗资约29.76万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667076446","title":"宜明昂科-B(01541)9月16日斥资29.76万港元回购9.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667076446","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667076446?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:50","pubTimestamp":1789555805,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年9月16日，该公司斥资29.76万港元回购9.24万股股份，每股回购价3.155-3.27港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.0415},{"period":"1month","weight":-0.1136},{"period":"3month","weight":-0.2086},{"period":"6month","weight":-0.2768},{"period":"1year","weight":-0.6494},{"period":"ytd","weight":-0.5249}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.125053},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.059944},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.036378},{"month":4,"riseRate":0.666667,"avgChangeRate":0.020918},{"month":5,"riseRate":0.333333,"avgChangeRate":0.218025},{"month":6,"riseRate":0.333333,"avgChangeRate":0.064638},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.092027},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.068233},{"month":9,"riseRate":0.666667,"avgChangeRate":0.059238},{"month":10,"riseRate":0.25,"avgChangeRate":-0.127974},{"month":11,"riseRate":0,"avgChangeRate":-0.121088},{"month":12,"riseRate":0,"avgChangeRate":-0.128943}],"exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}